Background The aim of this study was to assess the role of skin rash in predicting the
efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and the …

BACKGROUND: Dermatological toxicity, usually in the form of acneiform rash, is frequently
observed in non-small-cell lung cancer (NSCLC) patients treated with anti-EGF receptor …

Objectives Nivolumab has recently received regulatory approval as a 2nd-line treatment of
non-small cell lung cancer (NSCLC). The data regarding its effectiveness and safety in real …

Purpose As epidermal growth factor receptor (EGFR) inhibitors are associated with a variety
of dermatologic adverse events (dAEs), the purpose of this study was to develop an …

Background Adherence to erlotinib could be a determinant for clinical outcome and
treatment toxicity in patients with advanced non–small-cell lung cancer (A-NSCLC). Patients …

Erlotinib is a potent inhibitor of epidermal growth factor receptor tyrosine kinase and has
been demonstrated to treat advanced or metastatic non-small cell lung cancer to prolong …

Lung cancer is the leading cause of cancer deaths worldwide. Targeting the epidermal
growth factor receptor (EGFR) has played a central role in advancing non-small-cell lung …

Objectives An association between skin toxicity and outcome has been reported for NSCLC
patients treated with erlotinib. Several explanations have been suggested, including …

Background: Brain metastases commonly occur in non–small cell lung cancer (NSCLC), and
patient prognosis is poor. Erlotinib, a specific inhibitor of epidermal growth factor receptor …

Erlotinib is an orally small molecule inhibiting the tyrosine kinase activity of the epidermal
growth factor receptor (EGFR). Currently, erlotinib, at a standard oral daily dose of 150 mg, is …